Prescription patterns of ambrisentan in some cities of Colombia
| Autor: | Luis Fernando Valladales‐Restrepo, Andrés Gaviria‐Mendoza, Manuel Enrique Machado‐Duque, Álvaro Vallejos‐Narváez, Jorge Enrique Machado‐Alba |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | The Clinical Respiratory Journal, Vol 18, Iss 3, Pp n/a-n/a (2024) |
| Druh dokumentu: | article |
| ISSN: | 1752-699X 1752-6981 |
| DOI: | 10.1111/crj.13736 |
| Popis: | Abstract Introduction Ambrisentan is a selective type A endothelin receptor antagonist that has shown significant effectiveness and safety in the management of patients with pulmonary hypertension. Its use pattern with real‐world evidence in Colombia is unknown. Objective The objective of this study is to determine the prescription patterns of ambrisentan in some cities of Colombia. Methods A longitudinal descriptive study on the prescription patterns of ambrisentan in patients with pulmonary hypertension (all the groups) was conducted between January 2021 and December 2022 based on a population database of members of the Colombian Health System. Adherence at 1 year was determined using the Medication Possession Ratio (days the drug was dispensed/days from first dispensing to the end of the follow‐up period × 100). Descriptive analysis was carried out. Results Sixty‐seven patients taking ambrisentan were identified in 10 cities of the country. The individuals had a median age of 51.5 years (interquartile range‐IQR: 39.8–64.0 years), and 82.1% were women. The drug possession rate was 82.2% (IQR: 65.0–96.8%), and persistence at 1 year was present in 49.3% (n = 33) of the cases. The average dose was 8.8 ± 5.0 mg/day, and 76.1% (n = 51) received it in combination therapy, mainly with phosphodiesterase type 5 inhibitors (61.2%, n = 41). Conclusions Adherence to ambrisentan was good, but its persistence at 1 year was low. The dosages of the drug used were in accordance with the recommendations of the clinical practice guidelines, and it was used in combination therapy, especially with phosphodiesterase 5 inhibitors. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|